Ziprasidone Intramuscular Injection Suppliers & Bulk Manufacturers
Available Forms: Intramuscular Injection (IM)
Available Strengths: 20 mg/mL
Reference Brands: Zeldox®(EU); Geodon®(US)
Category:
Antipsychotropic Drugs
Ziprasidone is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors, helping to rapidly reduce acute psychotic symptoms and agitation. The intramuscular (IM) formulation is used for the short-term treatment of acute agitation in patients with schizophrenia. It provides fast onset of action, making it ideal for emergency settings when rapid behavioral control is needed.
Ziprasidone Intramuscular Injection is available in Intramuscular Injection (IM)
and strengths such as 20 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ziprasidone Intramuscular Injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ziprasidone Intramuscular Injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ziprasidone intramuscular injection (brand name: Geodon) is FDA-approved in the United States for the acute treatment of agitation in patients with schizophrenia. It is intended for short-term use when rapid control of symptoms is clinically necessary. In the European Union, it is approved under the name Zeldox for similar indications. Regulatory approval requires GMP-compliant injectable manufacturing, validated safety and efficacy data, and pharmacokinetic studies supporting rapid onset. U.S. labeling includes warnings for QT interval prolongation and cardiac risk. EU approvals require Risk Management Plans (RMPs) and ongoing pharmacovigilance. For sourcing and dossier-ready options, visit Pharmatradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing